Per has more than 25 years’ experience in the biotech and pharmaceutical industry within product development and business development. He has founded and run several biotech companies, worked as a biotech consultant and been an entrepreneur in residence with Novo Holdings. His primary therapeutic areas of interest have been immunology, vaccines, haemostasis and oncology. Per holds a D.Phil. from the University of Oxford and has 6 years of laboratory experience within immunology and infectious diseases prior to starting his industrial career.

Lidia has more than 25 years’ R&D experience in the industry, with focus on clinical development, both in pharmaceutical companies and in biotech. She spent more than 20 years of her industry career in development of prophylactic vaccines and has led several large phase 3 clinical programs. She holds a Medical Degree from the University of Ghent (Belgium) and is specialized in Pharmaceutical Medicine.

Bengt holds a PhD in Immunotechnology from Lund University. He has 20 years of experience heading research groups at Lund University and Denmark Technical University (DTU) within the research areas of immunology, vaccinology, and infectious disease. He has been the main supervisor for several completed PhD and postdoctoral projects. In parallel to his current assignment as the CSO of MinervaX, Bengt is an Associate Professor at the Faculty of Medicine, Lund University.

Bjorn has more than 15 years’ experience within the field of bacterial vaccines. He joined MinervaX in 2021, and currently serves as Chief Technology Officer and Head of Chemistry Manufacturing and Controls (CMC). Prior to MinervaX, Bjorn was at Lundbeck, where he helped build the Biopharmaceutical Division. Prior to Lundbeck, Bjorn was head of a QC department at the CMO AGC Biologics (former CMC Biologics) and prior to that, he served as laboratory leader and assay development scientist at Statens Serum Institut. He received an M.Sc in Biotechnology from the Technical University of Denmark and a Ph.D from the University of Copenhagen.

Ms. Genthe has +25 years’ experience in Regulatory Affairs, including leading FDA inspections and major filings, including the submission for palivizumab (Synagis®), the first monoclonal antibody developed into a vaccine. Ms. Genthe received a M.Sc in Biotechnology from Johns Hopkins University in Maryland. Ms. Genthe joined MinervaX in 2024, and currently serves as Senior Vice President of Quality and Regulatory. Prior to MinervaX, Ms. Genthe was Vice President of Regulatory Affairs at GeoVax. Prior to GeoVax, Ms. Genthe served in several senior regulatory leadership positions at Pfizer, Teva, and Genpact.